Navigation Links
Pete Doherty Gets a Rehab or Jail Ultimatum

Singer Pete Doherty has been given an ultimatum; that he will face jail if he doesn't undergo rehab to deal with his drug abuse.

The Babyshambles frontman pleaded guilty to possessing quantities of crack cocaine, heroin, cannabis and ketamine as well as two driving offenses at a hearing in London on July 3.

Judge Davinder Lachhar told Doherty that he would only steer clear of jail if he enters rehab before August 7, when he is due to be sentenced.

"If you go to this place to have detox and take advantage of it then we will see what sentence is appropriate when you next come. But if you do not I can tell you now that you will go into custody," The Sun quoted District Judge Davinder Lachhar, as stating in the courtroom.

Speaking to reporters outside court, Doherty, who is currently dating supermodel Kate Moss, said that this ruling pushed his already thought-out rehab plans.

"I have got no choice, have I. It's rehab or jail. I was going to rehab anyway to be honest with you - this is just a little push," Doherty said.

Judge Lachhar said that she decided to give Doherty another chance, after learning that he had been offered the chance to undergo rehab in Harrogate, northern England, later this month.

These six offences are all related to his arrest on May 5 when his car was stopped by officers in Kensington High Street, London.


'"/>




Page: 1

Related medicine news :

1. Pete Doherty Set for Another Drug Trial
2. Pete Doherty "not Ready" to Quit Drug Use
3. Doherty Will Marry Moss If Hes smack and Needle-free
4. Supermodel Kate Moss Brands Pete Doherty The Slug
5. Cops Fine Doherty for Littering
6. Kate Moss to Pay for Dohertys Anti-heroin Implant
7. Kate Moss Takes Refuge With Pal After Break-up With Doherty
8. Cardiac – Rehabilitation Programs Beneficial for Heart Patient
9. Rehabilitate Sex Workers - Mata Amritanandamayi
10. Book Seeks To Rehabilitate Soldiers
11. States Urged By NHRC To Rehabilitate Cured Mental Patients
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Pete Doherty Gets Rehab Jail Ultimatum

(Date:12/2/2008)... CHICAGO, Dec. 2 Breast-Specific ...ly sensitive imaging technique for the diagnosis o...o diagnose breast cancer. BSGI,is a molecular bre...dent of,tissue density and discover very early st...ound and magnetic resonance imaging (MRI), BSGI ha...
(Date:12/2/2008)... PHILADELPHIA, Dec. 2 U...lvania children the opportunity to become "health,... designing programs to,address it and implementin...edHealth HEROES is a service-learning, health lite...e, working through educators and youth,leaders, t...
(Date:12/2/2008)... Money may be better spent in other areas, expert...s) -- Hospital rapid response teams, created to pr...patients, do not seem to work, a new study finds. ...over the past decade," said lead researcher Dr. Pa...t Institute in Kansas City, Mo. "Earlier studies h...
(Date:12/2/2008)... , The Health Story Proje...he project formerly known as “Clinical Docum...(CDA4CDT). CDA4CDT will continue as the label for ...nd submitted to Health Level Seven (HL7) for ballo... (Business Wire EON) December 2, 2008 -- "Ou...
Breaking Medicine News(10 mins):Health News:Molecular Breast Imaging Has Greater Sensitivity Over Mammography, Ultrasound and MRI for Invasive Lobular Carcinoma 2Health News:UnitedHealth Group Grants to Help Students and Educators Combat Childhood Obesity 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 2Health News:Rapid Response Teams Don't Cut Hospital Heart Attacks, Death Rates 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 2Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 3Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 4Health News: "The Health Story Project" Adopted as New Brand by CDA4CDT : New Brand Underscores Comprehensive Electronic Health Records 5
...led that there has been an increase in heart failu...s are higher among women, // with men surviving f...n the incidence of heart failures during the 1990 ...eriod, in the case of people aged over 65 years, a...
...ent has approved the drug TEMODAL in combination w...astoma multiforme brain cancer. // The drug TEMODA...ng-Plough Corporation and is used in treating two ...forme and anaplastic astrocytoma. Clinical study ...
...to India’s National Institute of Immunology are re...ch helps us to understand how the tuberculosis (TB...ll help in developing newer and more effective med...y as 2 million lives across the world annually. Th...
... the worst possible results does not serve any pur...he disappointment in the end is the same for both ...ttle Pacific University and Jonathon Brown of the ...hnique of ‘defensive pessimism’ and reported their...
Other Medicine News:
(Date:12/2/2008)...c. 2 Horizon Therapeutics, Inc., a...announced that two pivotal,Phase 3 trials evaluat...T-501,met all primary endpoints. HZT-501, a nove...taining ibuprofen and famotidine, demonstrated a,...ce of non-steroidal,anti-inflammatory drug (NSAID...
(Date:12/1/2008)... CHICAGO, Dec. 2 A stu...EM), a new technique for imaging the breast, is no...ormonal status, two factors that limit the effecti...g cancer. Results will be presented today at the a... America (RSNA). , , "The ability of PEM t...
(Date:12/1/2008)...1 S*BIO Pte Ltd today announced th...18, a potent and orally-active JAK2 inhibitor, in ...with chronic idiopathic myelofibrosis (CIMF). , ...ty and tolerability of SB1518 in patients with CIM... Phase 1 part of the study will assess the safety ...
(Date:12/1/2008)...hows the Prox1 gene is a two-way switch that, if t...e reprogrammed so that they lose their identity an..., MEMPHIS, Tenn., Dec. 1 /PRNewswire-USNewswire/...spital have discovered that a certain differentiat...at it requires the constant expression of a gene c...
Breaking Medicine Technology:Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4New Mammography Technology Effective in Detecting Breast Cancer 2New Mammography Technology Effective in Detecting Breast Cancer 3New Mammography Technology Effective in Detecting Breast Cancer 4S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 2Reprogrammable Cell Type Depends on a Single Gene to Keep Its Identity 3JAMA Commentary Opposes Criminal Punishment for HIV Exposure Transmission 6916 1JAMA Commentary Opposes Criminal Punishment for HIV Exposure Transmission 6916 2JAMA Commentary Opposes Criminal Punishment for HIV Exposure Transmission 6916 3Kowa Company Ltd Acquires ProEthic Pharmaceuticals Inc 6913 1Kowa Company Ltd Acquires ProEthic Pharmaceuticals Inc 6913 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 6909 1Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 6909 2Lilly Reaffirms Purchase Offer for SGX Pharmaceuticals 6909 3Huifeng Bio Pharmaceutical 28HFGB 29 to Release Second Quarter 2008 Earnings Results on August 15 2008 6904 1
...ion during the,early post-operative period compare...ion in nausea in the female,patient population com... CeNeS Pharmaceuticals plc (AIM:,CEN), the Cambrid...tional data from post-hoc analysis of the recent P...nide) in over 500 patients,with post-operative pai...
...0%; mso-hyphenate: none">,BUDAPEST, Hungary, June,...sands of patients with cancer from suffering,unnec...ngress of,the European Association for Palliative ...ated whether this first in class novel,formulation...,duration of effect, mirroring the breakthrough pa...
Other Medicine Technology:Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 2Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 3Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 4Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 5Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 6Further Statistical Analysis of the Recent Phase III trial on Lead,Product M6G Shows Additional Benefits 7Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 2Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 3Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 4Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 5Trial Results with Intranasal Fentanyl Hold Promise for Treatment,of Breakthrough Pain in Cancer 6
Inquire
Inquire
...nce, the SZX7 is designed for ease of use and work...ns to advanced research. The SZX7 offers one of th...ding image clarity, true color and accurate reprod...ined detail. System modularity and abundant access...
A compact stereomicroscope that is immediately ready for operation and extremely easy to use. Focused on the essential performance features, the Stemi DV4 design concept provides optimum utility.
Medicine Products: